![]() |
|
|
Vol. 286, Issue 2, 977-983, August 1998
Shionogi Research Laboratories, Shionogi & Co., Ltd., Futaba-cho,
Toyonaka, Osaka 561, Japan
We studied the possible participation of endothelin-1 (ET-1) in
the pathogenesis of renal damage in glycerol-induced acute renal
failure (ARF). Cortical mRNA expression of ET-1 increased, peaking at
10 hr postinjury, but this did not occur in the medulla, plasma
concentration and urinary excretion of ET-1 also increased in this
model. There was no change in ETA receptor mRNA, whereas the ETB
receptor tended to be down-regulated in the kidney after glycerol
administration. In situ hybridization study demonstrated that elevated expression of prepro ET-1 was predominantly localized in
cells in the proximal tubules of the nephritic kidney. The administration (30-3 mg/kg) of S-0139, (+)-disodium
27-[(E)-3-[2-[(E)-3-carboxylatoacryloylamino]-5-hydroxyphenl]acrylayloxy]-3-oxoolean-12-en-28-oate, an ETA selective antagonist, after initiation of insult offered dose-dependent prevention against ARF, demonstrating preventing of
renal function impairment and mortality. These findings indicate that
ET-1 participates in the pathogenesis of acute tubular injury in
glycerol-induced ARF and that ETA antagonist may be useful in the
treatment of some types of human ARF.
This article has been cited by other articles:
![]() |
Y. Matsumura, T. Kuro, Y. Kobayashi, F. Konishi, M. Takaoka, J. L. Wessale, T. J. Opgenorth, C. E. Gariepy, and M. Yanagisawa Exaggerated Vascular and Renal Pathology in Endothelin-B Receptor-Deficient Rats With Deoxycorticosterone Acetate-Salt Hypertension Circulation, November 28, 2000; 102(22): 2765 - 2773. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Clozel, H. Ramuz, J.-P. Clozel, V. Breu, P. Hess, B.-M. Löffler, P. Coassolo, and S. Roux Pharmacology of Tezosentan, New Endothelin Receptor Antagonist Designed for Parenteral Use J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 840 - 846. [Abstract] [Full Text] |
||||